SCHEMBL14719786

SCHEMBL14719786

CC(C)c1cc2[nH]c(=O)n(NS(=O)(=O)CC(=O)CN3CCOCC3)c(=O)c2cc1-c1ccnn1C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.36
IMPDH2 P12268 1/20 0.34
HSD17B10 Q99714 2/20 0.34
HTR2A P28223 9/20 0.34
HTR2C P28335 5/20 0.34
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
EED O75530 1/20 0.33
RBBP4 Q09028 1/20 0.33
SUZ12 Q15022 1/20 0.33
EZH2 Q15910 1/20 0.33
AEBP2 Q6ZN18 1/20 0.33
HTR3A P46098 3/20 0.33
CHUK O15111 1/20 0.32
MAPK8 P45983 1/20 0.32
CAMKK2 Q96RR4 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597376 0.80 IMPDH2 (0.35) CD274IMPDH2HSD17B10HTR2AHTR2C
Selurampanel SCHEMBL30259242 0.80 HAVCR2 (0.34) IMPDH2
Selurampanel SCHEMBL1660562 0.80 HAVCR2 (0.34) IMPDH2
SCHEMBL2597358 0.77 IMPDH2 (0.36) CD274IMPDH2HSD17B10HTR2AHTR2C
SCHEMBL2597134 0.76 HAVCR2 (0.33)
SCHEMBL2597215 0.76 ALDH1A1 (0.37) CD274IMPDH2HSD17B10HTR2AHTR2C
SCHEMBL2599232 0.74 LIPG (0.35)
SCHEMBL1661254 0.74 HAVCR2 (0.34)
SCHEMBL1661007 0.73 IDH1 (0.35)
SCHEMBL14719753 0.72 LIPG (0.34) HSD17B10ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES GRIK2, GRIK1, GRIK4 CD274 2713/4885IMPDH2 1186/4885HSD17B10 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.